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Abstract 
Placebo effects are well-known phenomena in medicine and biology.  In fact, placebos are used as 
control conditions in randomized cross-over clinical trials to validate new treatments. Only recently, 
however, has it become apparent that the conditioning and/or expectation effects provided by the 
experience of placebos can influence the results of clinical trials. It seems that combining shams and 
sequences has prejudiced the conclusions provided by cross-over designs.  Frighteningly, this bias is 
always in the same direction, namely to increase the risk of rejecting potentially valid treatments. New 
models for clinical trials should be encouraged if we wish to market new and truly valid treatments. 
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Are placebo-controlled cross-over designs in clinical trials silently killing new and promising 
treatments?  Raising this question could seem heretic, especially in an age where evidence-based 
medicine and bias-prevention constitute omnipresent concerns.  Sadly, this may be happening every 
day, hiding in plain view of our collective ignorance.  The proverbial fly in the ointment seems to be in 
the nature of the design itself – a design which exposes participants to multiple interventions, often in 
close succession. Although multiple treatment expositions offer several recognized advantages (e.g., 
preventing the prejudicial effects provided by inter-individual differences and decreasing the number of 
participants needed to obtain appropriate statistical power), they also promote unsuspected carry-over 
effects which can negatively influence the confirmation of new treatments.  Cross-over designs, 
therefore, may be designed to favor bias. 
 
The problem: Placebo effects carry consequences 
This tendency to favor bias was made obvious in a recent study published by Andre-Obadia and 
colleagues1.  In their study, the authors used a double-blind, randomized, cross-over design to 
investigate the analgesic effects of repetitive transcranial magnetic stimulation (rTMS), and found that 
posteroanterior rTMS was more effective than sham and/or lateromedial rTMS.  Interestingly, the 
authors observed that the analgesic effects induced by posteroanterior rTMS were easier to demonstrate 
when compared with lateromedial rTMS than when compared with sham-rTMS.  This observation led 
Andre-Obadia et al. to conduct a second study in which they specifically evaluated sequence effects 
(i.e., pertaining to the timing of the different interventions within the protocol)2.  They found that the 
sham intervention significantly decreased pain when it followed a successful rTMS session.  On the 
other hand, there was a tendency for sham-rTMS to increase pain when it followed an unsuccessful 
rTMS session.  Only when the sham intervention was applied first did it provide scores that were 
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comparable to baseline (i.e., no intervention at all).  Taken together, these observations indicate that the 
efficacy of past treatments can have a major impact on the efficacy of future treatments, even when 
these future treatments are designed as inactive controls.  This means that placebo interventions may 
not be, and perhaps have never been, valid control conditions in randomized crossover trials. 
From a theoretical perspective, the observations of Andre-Obadia et al.2 can be explained by the
conditioning model of placebo analgesia3.  According to classical conditioning theory, the repeated
experience of an effective analgesic treatment (the unconditioned stimulus) facilitates the development 
of robust associations between active treatment effects (in this case active rTMS-induced analgesia) 
and the surrounding environment (laboratory, rTMS coil, experimenter, etc.).  Once the conditioning 
phase is over, simply presenting the neutral stimulus can produce the unconditioned response, even in 
the absence of active ingredients.   Although this issue is still debated in the field, it is generally 
admitted that the conditioning effect for pain and other conscious processes relies heavily on 
expectations created during the conditioning phase4.  A few reviews address the influence of
expectations, conditioning, and, other confirmatory phenomena in placebo studies3, 5-7.  However,
regardless of the variables which may affect placebo and placebo-like phenomena,  it is important to 
point out that, in clinical trials,  pre-crossover conditions may very well produce conditioned responses 
which can affect post-crossover conditions. 
Of course, conditioned responses are not limited to placebo or sham conditions, but may also 
affect active treatments.  Thus, given the right circumstance, it may be possible to kill the efficacy of 
valid treatments.  We recently observed this phenomenon in a study designed to investigate the 
involvement of endogenous opioids in high-frequency TENS analgesia8.  Specifically, we found that
when TENS was first experienced as ineffective (because of opioid blockade with naloxone) the 
analgesic effect of all subsequent TENS treatments were completely blocked, even though naloxone 
was never again provided. Had sequence effects been ignored, we would have erroneously concluded 
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that high-frequencey TENS was not opioidergic.  In our study participants never experienced TENS 
prior to their participation.  This is worth mentioning because prior experience of the treatment at hand 
might have influenced treatment efficacy during the first condition, and thus, might have further 
influenced carry-over effects.  Given this possibility, it is always a good idea to take prior treatment 
experiences into consideration before conducting clinical trials. 
The study of Andre-Obadia et al.2 and our study8 represent opposite sides of the same 
conditioning coin.  On the one hand, the study of Andre-Obadia et al. illustrates that an effective 
treatment can have positive carry-over effects that can render inert treatments effective, and, on the 
other hand, our study shows that an ineffective treatment can have negative carry-over effects that can 
render active treatments ineffective.  These findings suggest that even under stable conditions and 
even in the absence of important disease-induced fluctuations (two important prerequisites when 
conducting cross-over designs)9, 10, the results obtained from cross-over designs need to be interpreted 
cautiously, and perhaps even questioned outright.  In particular, the present studies constitute eloquent 
examples of why crossover designs run the risk of providing false negatives, either because placebo 
controls become active and thus hard to beat or because active treatments are rendered completely 
ineffective.  We wish to point out here that it may still be possible for new treatments to survive the 
biasing effects inherent to cross-over designs, and thus outperform shams.  When this happens, 
researchers can be quite sure that the new treatment they are investigating is truly potent.  
Unfortunately, short of being extremely potent, many new (and effective) drugs may not survive the 
biasing effects of carry-over, and thus be cavalierly dismissed. 
 
                                                 
 Treatment failure in our study was caused by the use of naloxone, which provoked a strong abolition of analgesia.  On the 
other hand, treatment failure in conventional clinical trials is typically caused by the use of an inactive substance (i.e., a 
placebo), which likely provokes a milder degree of treatment failure.  As a result, researchers can probably expect weaker 
negative carry-over effects than ours when running conventional clinical trials.  Nevertheless, negative carry-over effects 
remain a very real possibility; even in placebo-controlled cross-over trials. 
Reassessing randomized clinical trials   6 
Decaying treatment effects may be the solution 
In their paper, Andre-Obadia et al.2 suggested two solutions to try and correct for conditioning
effects.  The first solution proposed by the authors was to dismiss the use of placebos in cross-over 
designs and use only active interventions.  In our opinion, this strategy does not address the problem 
since the experience made during the first intervention can still influence the response to the second 
intervention, even if the second intervention is an active treatment.  Hence, comparisons made only 
between active treatments are not the solution to the ill-effects of crossover designs.  The second 
solution proposed by the authors is to change the random nature of presentation by specifically 
favoring placebos as the first condition.  This would have the advantage of preventing positive carry-
over effects stemming from the initial experience of active treatments. However, this strategy will not 
correct for the negative carry-over effects stemming from the initial experience of placebo interventions, 
and thus, again, does not constitute a valid solution to the conditioning problem. 
We propose an alternative solution, based on the observations made a number of years ago by 
Fedele and colleagues11.  In their study, the authors noted a positive treatment effect during placebo
trials which, interestingly, disappeared progressively following repeat exposures to placebos11, 12.  Sadly,
the results published by Fedele et al. have languished in obscurity, and researchers have failed to 
exploit the progressive decline in placebo efficacy observed by the authors.  Building on Fedele et al.'s 
results, it is possible to propose a new approach to clinical research trials, one which would follow 
treatments over time, as described in Table 1.  This would allow researchers (1) to document and study 
resistance to extinction, a property of active but not placebo treatments, and, (2) to identify the 
appropriate time point to use when comparing active and placebo treatments. 
Evidently, the solution we propose has the disadvantage of increasing the cost and duration of 
clinical trials.  We nevertheless believe this to be necessary in order to ensure the validity of results 
obtained from cross-over designs.  The time needed for conditioning and/or expectation effects to 
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extinguish remains uncertain, and likely to vary as a function of conditioned effects.  Clearly, future 
studies are needed to evaluate the time needed for conditioning and/or expectation effects to extinguish, 
and, to study the impact this may have on the running of clinical trials. 
Conclusion 
In conclusion, the study of Andre-Obadia et al.2 and the study of Leonard et al.8 illustrate that the
results of cross-over designs need to be interpreted cautiously.  The reader must also acknowledge that 
sequence effects do not only affect pain research.  Indeed, placebo effects are observed in a wide 
variety of other conditions and treatments13, making it probable that sequence effects are also present in
cross-over designs aimed at evaluating the efficacy of treatments in other health conditions.  The use of 
cross-over designs that include measurements at multiple time points represent, in our view, a viable 
solution for researchers who wish to continue using cross-over designs, but who do not want to run the 
risk of erroneously shelving promising new treatments.  The field is ready for novel research studies 
and targeted review papers on this potentially influential issue.
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Table 1.  Repeated measures strategy proposed for cross-over designs 
Active Condition First Placebo Condition First 
Presentation 
order Condition Expected response 
Presentation 
order Condition Expected response 
1 Active treatment Effective 1 Placebo treatment Effective 
2 Active treatment Effective 2 Placebo treatment Partially effective 
3 Active treatment Effective 3 Placebo treatment Ineffective 
4 Active treatment Effective 4 Placebo treatment Ineffective 
-- Crossover -- -- Crossover -- 
5 Placebo treatment Effective 5 Active treatment Ineffective 
6 Placebo treatment Partially effective 6 Active treatment Partially effective 
7 Placebo treatment Partially effective 7 Active treatment Effective 
8 Placebo treatment Ineffective 8 Active treatment Effective 
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